Loading...
Docoh

Emergent Biosolutions (EBS)

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.

Company profile

Ticker
EBS
Exchange
CEO
Robert Kramer
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
400 Professional LLC • Adapt Pharma Inc. • Cangene bioPharma LLC • Emergent Commercial Operations Frederick Inc. • Emergent Biodefense Operations Lansing LLC • Emergent Europe Inc. • Emergent International Inc. • Emergent Manufacturing Operations Baltimore LLC • Emergent Product Development Gaithersburg Inc. • Emergent Protective Products USA Inc. ...
IRS number
141902018

EBS stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

1 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 358.3M 358.3M 358.3M 358.3M 358.3M 358.3M
Cash burn (monthly) 25.9M 7.45M 27.6M (no burn) 5.2M (no burn)
Cash used (since last report) 79.2M 22.78M 84.4M n/a 15.9M n/a
Cash remaining 279.1M 335.52M 273.9M n/a 342.4M n/a
Runway (months of cash) 10.8 45.0 9.9 n/a 65.8 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 22 Sujata Tyagi Dayal Common Stock Grant Acquire A No No 0 11,852 0 11,852
9 Jun 22 Kathryn C Zoon Common Stock Sell Dispose S No No 31.52 1,173 36.97K 19,654
26 May 22 Kathryn C Zoon Common Stock Grant Acquire A No No 0 8,446 0 20,827
26 May 22 Richard Ronald Common Stock Grant Acquire A No No 0 8,446 0 21,749
21.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 227 250 -9.2%
Opened positions 22 47 -53.2%
Closed positions 45 49 -8.2%
Increased positions 63 76 -17.1%
Reduced positions 100 95 +5.3%
13F shares Current Prev Q Change
Total value 1.26B 1.75B -28.2%
Total shares 40.41M 41.34M -2.3%
Total puts 30.3K 82.3K -63.2%
Total calls 121.6K 106.7K +14.0%
Total put/call ratio 0.2 0.8 -67.7%
Largest owners Shares Value Change
BLK Blackrock 8.53M $264.86M -2.3%
Vanguard 5.09M $158.01M -1.3%
STT State Street 4.15M $128.84M +19.6%
Dimensional Fund Advisors 1.95M $60.44M +42.3%
Earnest Partners 1.84M $57.26M -10.9%
Jacobs Levy Equity Management 1.09M $33.71M +115.8%
D. E. Shaw & Co. 1.07M $33.09M -8.4%
Geode Capital Management 831.95K $25.82M +1.7%
IVZ Invesco 820.6K $25.47M -7.5%
MS Morgan Stanley 700.1K $21.73M +60.0%
Largest transactions Shares Bought/sold Change
JHG Janus Henderson 73.1K -720.23K -90.8%
STT State Street 4.15M +681.16K +19.6%
Jacobs Levy Equity Management 1.09M +582.59K +115.8%
Dimensional Fund Advisors 1.95M +578.67K +42.3%
Marshall Wace 448.53K +448.53K NEW
Two Sigma Investments 16.71K -310.91K -94.9%
FHI Federated Hermes 22.03K -276.18K -92.6%
Manufacturers Life Insurance Company, The 20.45K -274.35K -93.1%
Renaissance Technologies 95K -263K -73.5%
MS Morgan Stanley 700.1K +262.45K +60.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AdVac, ancillary, antiviral, arbitration, Bio, brincidofovir, Chimerix, consummation, consumption, cumulative, curable, dispute, Ebanga, Ebola, iii, infusion, iv, Janssen, mediation, opposition, pause, recombinant, remeasurement, requisite, Ridgeback, Seller, serve, shorten, subsidiary, SymBio, TEMBEXA, unsuccessfully, upward, vi, vii, waiting, waiver
Removed: accumulation, appeal